Priunta 440mg

Priunta 440MG Inj is a brand name for Trastuzumab 440mg Injection, which is a medication used to treat certain types of cancer. Here are some key points about the product:

Composition:

Each 440mg injection of Priunta contains 440mg of Trastuzumab, a humanized monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2) protein.

Indications:

Trastuzumab is indicated for the treatment of:

1. HER2-positive metastatic breast cancer (MBC) in combination with chemotherapy
2. HER2-positive early breast cancer (EBC) in combination with chemotherapy and radiotherapy
3. Adjuvant breast cancer treatment in combination with chemotherapy and radiotherapy
4. HER2-positive metastatic gastric cancer (GC)

Mechanism of Action:

Trastuzumab works by:

1. Binding to HER2 protein on the surface of cancer cells
2. Inhibiting the growth and spread of cancer cells by blocking the signaling pathways that promote tumor growth
3. Reducing the production of growth factors that promote tumor growth

Dosage and Administration:

The recommended dosage of Priunta is:

• 440mg administered as an intravenous infusion every 3 weeks
• The dosage may be adjusted depending on the patient’s response to treatment

Side Effects:

Common side effects of Priunta include:

1. Fatigue
2. Fever
3. Chills
4. Headache
5. Nausea and vomiting
6. Diarrhea
7. Abdominal pain
8. Rash or skin changes
9. Increased risk of heart problems

Serious side effects can include:

1. Cardiac dysfunction or failure
2. Respiratory failure
3. Severe allergic reactions
4. Infusion-related reactions
5. Hemolytic uremic syndrome (HUS)

Contraindications:

Priunta is contraindicated in patients with:

1. Known hypersensitivity to trastuzumab
2. History of cardiac dysfunction or failure
3. Severe allergic reactions to humanized antibodies
4. Pregnancy or breastfeeding (unless absolutely necessary)

Precautions:

1. Patients with a history of cardiovascular disease or cardiac dysfunction should be closely monitored while receiving Priunta.
2. Patients with a history of blood disorders should be closely monitored for signs of blood dyscrasias.
3. Patients with a history of kidney disease or kidney dysfunction should receive dose reduction or close monitoring while receiving Priunta.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of infection, such as fever, chills, or sore throat.
• Patients should be advised to report any changes in their appetite, nausea, or vomiting.
• Patients should be informed that they may experience bleeding or bruising during treatment.

Storage and Handling:

• Store injections at room temperature between 15°C and 30°C (59°F and 86°F).
• Do not expose to direct sunlight or moisture.
• Use within 28 days of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.